Literature DB >> 28058056

Healthcare and the Preventable Silent Killer: The Growing Epidemic of Hepatitis C in Pakistan.

Kamiar Alaei1, Mohammad Sarwar2, Shao Chiu Juan3, Arash Alaei4.   

Abstract

Entities:  

Keywords:  HCV; Integration; Pakistan, Medical Education; Syringe Use

Year:  2016        PMID: 28058056      PMCID: PMC5198582          DOI: 10.5812/hepatmon.41262

Source DB:  PubMed          Journal:  Hepat Mon        ISSN: 1735-143X            Impact factor:   0.660


× No keyword cloud information.
Dear Editor, Twelve years ago, research had proposed that Pakistan was becoming a “cirrhotic state” due to the increasing prevalence of liver diseases (1). Hepatitis C was described as a serious problem even then; in certain areas, up to a fourth of hospital beds were occupied by patients due to the complications of the Hepatitis C virus (HCV) infection. Villages were gripped by fear; no one knew whose life would be taken next by the deadly virus. The government made promises to prevent HCV through stringent regulations after seeing the effects that this deadly disease had. Sadly, they remain undelivered and Pakistan now has one of the highest rates of HCV, second only to Egypt. It is estimated that 5% - 10% of Pakistan’s population up to 19 million people have been infected by HCV (2, 3). An epidemic of this scale is unprecedented and is not subsiding anytime soon; there are approximately 240,000 new cases diagnosed in Pakistan every year (2). Neighboring countries do not have Hepatitis C (HCV) rates that come close to this. Iran for example, even with its high rate of injecting drug use (IDU), has an HCV prevalence of less than 0.5 % (4, 5). IDU can often explain a high prevalence of HCV in some countries; it is one of the main risk factors for the disease. Though IDU is present in Pakistan, it is not widespread. Thus, it cannot explain why HCV is so frequent there. Other factors have been attributed to the spread of HCV in Pakistan as well; including blood transfusions and street barbers. Attempts have even been made to tackle some of these issues. For instance, NGOs and provincial governments have tried to regulate blood banks for instance. However, the rates of HCV seem to only keep rising. The question must be asked, “What is different about this country?” How has this disease been able to get such a strong foothold? The first step in tackling this problem would be simply looking at a map. Pakistan has four major provinces; Punjab, Sindh, Balochistan and Khyber-Pakhtunkhwa. Punjab and Sindh have the highest prevalence of HCV; about 6.7% and 5%, respectively (6). Balochistan and Khyber-Pakhtunkhwa, on the other hand, face considerably lower prevalence, close to 1% each (2). The discrepancy in HCV prevalence between these provinces is obvious. The provinces that are most pervaded by HCV infection also are the most developed and have the largest population centers, where people are expected to enjoy greatest healthcare resources and thus the best healthcare outcomes. Ironically, it seems that healthcare access and HCV rates seem to go hand in hand; the districts that fare best on the Human Development Index in Pakistan present some of the highest prevalence of HCV (7). Astonishingly, it seems that healthcare access and HCV prevalence are related in Pakistan; in fact it is estimated that 70% of new HCV infections in Pakistan are attributed to routine medical procedures (3). Particularly concerning are infections caused by contaminated syringes, which are so prevalent in the healthcare settings. With 5-13 injections per capita given yearly, Pakistan has one of the highest rates of injection use in the world (2, 8). In fact, many doctors are considered to be more professional should they give injectable medicines (9). Culture has had an impact, as reused or unsterilized needles have been the major driver of HCV epidemic in Pakistan (3). This cultural misconception, in combination with unsafe injection practices, gives rise to the outbreak of HCV. There is no evidence of syringe shortage in Pakistan. And in fact, syringes are rather cheap, going for only about 2 - 7 rupees (US$.02 - $.07) each (8). For the most part, physicians do follow the standard guideline of medical procedures, and most patients are aware of the danger of HCV contraction via syringes (10). The real problem is the lack of oversight in private healthcare settings due to lax regulation. Medical staff working in the private sector often lack adequate training to handle and dispose of syringes, leading to more than half receiving needle stick injuries, putting them at a higher risk for HCV infection (11-13). Medical assistants and paramedics often do not have the expertise to properly administer injections. On top of this, few private medical facilities have the means to dispose of used syringes properly, which end up in municipal waste sites or open garbage fields (14). There, scavengers pick them up and in many cases repackage and sell them without proper sterilization. All of these factors contribute to a system that is ripe for disease. The question then becomes how to resolve this issue. As stated previously, HCV infection is not only treatable, but preventable as well. In fact, the incidence of this disease is almost negligible in developed countries. The best practices employed in these countries can also be applied in Pakistan. Firstly, education of medical staff, medical assistants and paramedics in the private sector can be emphasized to ensure proper syringe use and adequate disposal techniques. Secondly, appropriate disposal of used syringes with a strict ban on reusing syringes can be a feasible solution. Thirdly, the integration of HCV services in the existing health care system by providing short-term training of primary physicians with respect to active screening, early treatment and outreach. Fourthly, providing affordable treatment for HCV, which prevents further infections and is itself prevention. Lastly and most importantly, interagency collaboration between the government, healthcare system, and communities help disseminate useful information to enhance the public awareness of HCV transmission. By changing the social norm and advocating safe injection practices, HCV epidemic in Pakistan can be greatly reduced.
  10 in total

1.  Hepatitis C in Iran. How extensive of a problem is it?

Authors:  Shahin Merat; Hossein Poustchi
Journal:  Arch Iran Med       Date:  2012-05       Impact factor: 1.354

2.  Pakistan:a cirrhotic state?

Authors:  Khabir Ahmad
Journal:  Lancet       Date:  2004 Nov 20-26       Impact factor: 79.321

3.  Comparison of need and supply of syringes for therapeutic injections in Pakistan.

Authors:  Adnan Ahmad Khan; Momina Saleem; Huma Qureshi; Rashid Jooma; Ayesha Khan
Journal:  J Pak Med Assoc       Date:  2012-11       Impact factor: 0.781

4.  Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan.

Authors:  A J Khan; S P Luby; F Fikree; A Karim; S Obaid; S Dellawala; S Mirza; T Malik; S Fisher-Hoch; J B McCormick
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

5.  The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.

Authors:  A Sibley; K H Han; A Abourached; L A Lesmana; M Makara; W Jafri; R Salupere; A M Assiri; A Goldis; F Abaalkhail; Z Abbas; A Abdou; F Al Braiki; F Al Hosani; K Al Jaberi; M Al Khatry; M A Al Mulla; H Al Quraishi; A Al Rifai; Y Al Serkal; A Alam; S M Alavian; H I Alashgar; S Alawadhi; L Al-Dabal; P Aldins; F Z Alfaleh; A S Alghamdi; R Al-Hakeem; A A Aljumah; A Almessabi; A N Alqutub; K A Alswat; I Altraif; M Alzaabi; N Andrea; M A Babatin; A Baqir; M T Barakat; O M Bergmann; A R Bizri; S Blach; A Chaudhry; M S Choi; T Diab; S Djauzi; E S El Hassan; S El Khoury; C Estes; S Fakhry; J I Farooqi; H Fridjonsdottir; R A Gani; A Ghafoor Khan; L Gheorghe; M Gottfredsson; S Gregorcic; J Gunter; B Hajarizadeh; S Hamid; I Hasan; A Hashim; G Horvath; B Hunyady; R Husni; A Jeruma; J G Jonasson; B Karlsdottir; D Y Kim; Y S Kim; Z Koutoubi; V Liakina; Y S Lim; A Löve; M Maimets; R Malekzadeh; M Matičič; M S Memon; S Merat; J E Mokhbat; F H Mourad; D H Muljono; A Nawaz; N Nugrahini; S Olafsson; S Priohutomo; H Qureshi; P Rassam; H Razavi; D Razavi-Shearer; K Razavi-Shearer; B Rozentale; M Sadik; K Saeed; A Salamat; F M Sanai; A Sanityoso Sulaiman; R A Sayegh; A I Sharara; M Siddiq; A M Siddiqui; G Sigmundsdottir; B Sigurdardottir; D Speiciene; A Sulaiman; M A Sultan; M Taha; J Tanaka; H Tarifi; G Tayyab; I Tolmane; M Ud Din; M Umar; J Valantinas; J Videčnik-Zorman; C Yaghi; E Yunihastuti; M A Yusuf; B F Zuberi; J D Schmelzer
Journal:  J Viral Hepat       Date:  2015-12       Impact factor: 3.728

6.  Needle stick injuries among health care workers of public sector tertiary care hospitals of Karachi.

Authors:  Mubashir Aslam; Tahir Taj; Arif Ali; Waseem Mirza; Hammad Ali; Mudassir Iqbal Dar; Nasira Badar
Journal:  J Coll Physicians Surg Pak       Date:  2010-03       Impact factor: 0.711

7.  Frequency and awareness of hepatitis B and C in visitors of Hepatitis Awareness Mela.

Authors:  Minaam Abbas; Muhammad Fawwad Ahmed Hussain; Sajjad Raza; Lubna Shazi
Journal:  J Pak Med Assoc       Date:  2010-12       Impact factor: 0.781

8.  Dengue fever with hepatitis E and hepatitis A infection.

Authors:  Javed Yakoob; Wasim Jafri; Shaheer Siddiqui; Mehmood Riaz
Journal:  J Pak Med Assoc       Date:  2009-03       Impact factor: 0.781

9.  Injection practices and sharp waste disposal by general practitioners of Murree, Pakistan.

Authors:  N Z Janjua
Journal:  J Pak Med Assoc       Date:  2003-03       Impact factor: 0.781

Review 10.  Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data.

Authors:  Muhammad Umer; Mazhar Iqbal
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

  10 in total
  4 in total

1.  The Urgency to Mitigate the Spread of Hepatitis C in Pakistan Through Blood Transfusion Reform.

Authors:  Kamiar Alaei; Mohammad Sarwar; Arash Alaei
Journal:  Int J Health Policy Manag       Date:  2018-03-01

2.  Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections.

Authors:  Houssein H Ayoub; Laith J Abu-Raddad
Journal:  BMJ Open       Date:  2019-05-27       Impact factor: 2.692

3.  Patient Safety: A Deep Concern to Caregivers.

Authors:  A K Mohiuddin
Journal:  Innov Pharm       Date:  2019-08-31

4.  The Frequency of Hepatitis C and its Risk Factors Among Health Care Providers at Tehsil Headquarter Hospital, Hasilpur, Pakistan.

Authors:  Uffan Zafar; Ammar Hasan; Bilal Aslam; Zubair Khalid; Muhammad Usman Baig; Saba Akram
Journal:  Cureus       Date:  2018-08-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.